Streetbeat News

Regulatory

TOVX

Theriva Biologics has successfully reached its target patient enrollment for the VIRAGE Phase 2b trial of VCN-01 in combination with Gemcitabine/Nab-Paclitaxel for treating metastatic pancreatic cancer. The trial is being conducted across 15 sites in Spain and the USA.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:26 pm

LTRN

Lantern Pharma has received three FDA Rare Pediatric Disease Designations for its drug LP-184, targeting malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma. This brings the total to four RPDDs for the company.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:19 pm

SPRC

SciSparc shares rose following FDA approval to start a Phase IIb clinical trial for SCI-110, targeting Tourette syndrome.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:18 pm

SPRC

SciSparc has received FDA approval to begin a Phase IIb clinical trial for its drug SCI-110, aimed at treating Tourette Syndrome. This marks a significant step forward in the company's drug development process.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:18 pm

SNY

Sanofi's Sarclisa has received FDA approval for use as a first-line treatment for newly diagnosed multiple myeloma patients not eligible for stem cell transplants. This marks Sarclisa's third US approval and highlights its effectiveness in reducing disease progression.

Portfolio Pulse from Vandana Singh

September 23, 2024 | 12:16 pm

KMB

Schneider Electric and Kimberly-Clark have announced new Tax Credit Transfer (TCT) agreements to support grid resiliency and clean energy transition in the U.S. These agreements, facilitated by Schneider Electric, involve funding for four battery energy storage projects by Kimberly-Clark, leveraging the Inflation Reduction Act's tax credit transferability. The projects aim to advance renewable energy storage and generation, particularly in Texas.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:14 pm

SPY

Minneapolis Fed President Kashkari emphasized the strength of the labor market and expressed a desire to maintain it. He also stated that he won't declare victory over inflation yet.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:13 pm

SPRY

ARS Pharmaceuticals has announced that its Neffy Epinephrine Nasal Spray is now available by prescription in the U.S. This follows FDA approval for its use in treating Type I allergic reactions, including anaphylaxis.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:10 pm

BAK

Braskem has been selected by the U.S. Department of Energy to negotiate a $50 million award to enhance its UHMWPE production in Texas, focusing on the lithium-ion battery separator market.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:10 pm

AIMD

Ainos is set to begin a clinical study in Taiwan for its product VELDONA, targeting Sjögren's Syndrome. The company aims to complete all necessary regulatory approvals by Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:09 pm